News stories about Cerulean Pharma (NASDAQ:DARE) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cerulean Pharma earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.6827832263095 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Cerulean Pharma (DARE) traded down 5.17% during trading on Thursday, reaching $2.75. 11,838 shares of the company’s stock were exchanged. Cerulean Pharma has a 52 week low of $2.63 and a 52 week high of $35.80. The firm’s market capitalization is $7.98 million. The stock has a 50-day moving average price of $3.16 and a 200 day moving average price of $4.20.
Separately, ValuEngine cut shares of Cerulean Pharma from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.
Cerulean Pharma Company Profile
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.